Raising awareness of neuroendocrine cancers around the world

NET Cancer Day

November 10

Donate

May 14 2011

Scottish Medicines Consortium Approves Use of Sunitinib for Pancreatic NETs

The Scottish Medicines Consortium has approved the use of Sunitinib for pancreatic neuroendocrine tumor patients, ahead of a decision to introduce the same medicine in England. The SMC said that Sunitinib improved the quality of life for people who were suffering from pancreatic NET, a cancer affecting up to 240 people in the UK every year, typically between the ages of 40 and 60. In the first year of use, an estimated 16 people in Scotland are likely to be prescribed the drug. Cathy Bouvier, director of the NET Patient Foundation, said the move was very encouraging. “The results in this case have been superb, increasing survival times and quality of life.”
Extract taken from The Times Scotland  May 10, 2011